Conversion to sirolimus from cyclosporine may induce nephrotic proteinuria and progressive deterioration of renal function in chronic allograft nephropathy patients

被引:43
作者
Boratynska, M
Banasik, M
Watorek, E
Falkiewicz, K
Patrzalek, D
Szyber, P
Klinger, M
机构
[1] Wroclaw Med Univ, Dept Nephrol & Transplant Med, PL-50417 Wroclaw, Poland
[2] Wroclaw Med Univ, Dept Gen Vasc & Transplant Surg, PL-50417 Wroclaw, Poland
关键词
D O I
10.1016/j.transproceed.2005.12.023
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Antiproliferative and non-nephrotoxic properties of sirolimus have been exploited for treatment of patients with chronic graft dysfunction. In this paper we point to the possible association of nephrotic syndrome and renal impairment with rapid conversion from cyclosporine (CsA) to sirolimus in patients with chronic nephropathy. Five male patients, ages 34 to 56 years, with chronic renal failure in the course of glomerulonephritis, were transplanted between 1997 and 1999. For the first 49 to 65 months, the immunosuppressive regimen consisted of CsA, azathioprine (AZA), and prednisone. Thereafter, due to chronic nephropathy evidenced by biopsy, conversion to sirolimus was performed with sharp withdrawal of CsA. The serum creatinine level prior to conversion was 1.9 +/- 0.3 mg/dL. Trace to 86 mg/dL proteinuria was found in 3 patients, while 2 patients had about 200 mg/dL. After 2 to 4 months of sirolimus treatment the proteinuria progressed (558 +/- 183 mg/dL); edema, hypoproteinemia, hypoalbuminemia, and hyperlipidemia developed; and the serum creatinine increased to 3.5 +/- 0.8 mg/dL. Biopsies performed in three patients revealed new pathologic changes. After 4 to 5 months, we performed reconversion to calcineurin inhibitor. Proteinuria decreased to 0 to 150 mg/dL; nevertheless the serum creatinine was continuously rising. Six to 15 months after the conversion, 3 patients returned to dialysis. The fourth patient, who was earlier reconverted, has a serum creatinine level of 2.0 mg/dL after 15 months. In conclusion, conversion from CsA to sirolimus may induce nephrotic syndrome with progressive deterioration of renal function. Converted patients require careful monitoring of proteinuria and renal function. Early reconversion to calcineurin inhibitor may prevent progressive deterioration of graft function.
引用
收藏
页码:101 / 104
页数:4
相关论文
共 14 条
[1]   Comparison of acute rapamycin nephrotoxicity with cyclosporine and FK506 [J].
Andoh, TF ;
Burdmann, EA ;
Fransechini, N ;
Houghton, DC ;
Bennett, WM .
KIDNEY INTERNATIONAL, 1996, 50 (04) :1110-1117
[2]   Investigation of pediatric renal transplant recipients with heavy proteinuria after sirolimus rescue [J].
Butani, L .
TRANSPLANTATION, 2004, 78 (09) :1362-1366
[3]   Rapid conversion to sirolimus for chronic progressive deterioration of the renal function in kidney allograft recipients [J].
Citterlo, F ;
Scatà, MC ;
Violi, P ;
Romagnoli, J ;
Pozzetto, U ;
Nanni, G ;
Castagneto, M .
TRANSPLANTATION PROCEEDINGS, 2003, 35 (04) :1292-1294
[4]   Predictors of success in conversion from calcineurin inhibitor to sirolimus in chronic allograft dysfunction [J].
Diekmann, F ;
Budde, K ;
Oppenheimer, F ;
Fritsche, L ;
Neumayer, HH ;
Campistol, JM .
AMERICAN JOURNAL OF TRANSPLANTATION, 2004, 4 (11) :1869-1875
[5]   Rapamycin-associated post-transplantation glomerulonephritis and its remission after reintroduction of calcineurin-inhibitor therapy [J].
Dittrich, E ;
Schmaldienst, S ;
Soleiman, A ;
Hörl, WH ;
Pohanka, E .
TRANSPLANT INTERNATIONAL, 2004, 17 (04) :215-220
[6]   Acute rapamycin nephrotoxicity in native kidneys of patients with chronic glomerulopathies [J].
Fervenza, FC ;
Fitzpatrick, PM ;
Mertz, J ;
Erickson, SB ;
Liggett, S ;
Popham, S ;
Wochos, DN ;
Synhavsky, A ;
Hippler, S ;
Larson, TS ;
Bagniewski, SM ;
Velosa, JA .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2004, 19 (05) :1288-1292
[7]  
Kahan B D, 2001, Expert Opin Pharmacother, V2, P1903, DOI 10.1517/14656566.2.11.1903
[8]  
KAHAN BD, 2003, TRANSPLANT P, V35, P259
[9]   Use of rapamycin slows progression of cardiac transplantation vasculopathy [J].
Mancini, D ;
Pinney, S ;
Burkhoff, D ;
LaManca, J ;
Itescu, S ;
Burke, E ;
Edwards, N ;
Oz, M ;
Marks, AR .
CIRCULATION, 2003, 108 (01) :48-53
[10]  
Morris RE, 2001, TRANSPLANTATION, V71, pSS37